Additional Reading

Additional Reading

  • Abhishek A, Nakafero G, Kuo C, et al. Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink. Rheumatology. 2018;57:977-81.
  • Arts EE, Popa C, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis. 2015;74:668-74.
  • Aletaha D et al. 2010 Rheumatoid arthritis classification criteria: an American College of Radiology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-2581.
  • Burgers L, Raza K, van der Helm-van Mil A. Window of opportunity in rheumatoid arthritis – definitions and supporting evidence: from old to new perspectives. RMD Open. 2019;5:e000870.
  • Burmester G, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73:69–74.
  • Burmester GR, et al. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis. 2017; 76: 1279-1284.
  • Burmester GR, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76: 840-847.
  • Gabay C et al; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. 2013;381:1541-1550.
  • Grijalva CG, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. 2011;306:2331-9.
  • Genovese MC, et al. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology. 2018;57: 1423-1431.
  • Genovese MC, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate. Arth Rheum. 2015; 67: 1424-1437.
  • Hresko A, Solomon D. Medical care costs associated with rheumatoid arthritis in the US: A systematic literature review and meta-analysis. Arthritis Care Res (Hoboken). 2018;70:1431-8.
  • Kim HL, et al. Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach. Arch Pharm Res. 2014;37:662-70.
  • Kohler B, Gunther J, Kaudewitz D, Lorenz H. Current therapeutic options in the treatment of rheumatoid arthritis. J Clin Med. 2019;8:E938.
  • Mäki-Petäjä KM, et al. Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. 2012;126:2473-80.
  • Nakashita T, et al. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ 2014;4(8):e005615
  • Rao VU, et al. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol. 2015;67:372-80.
  • Schiff M, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73:86-94.
  • Singh J, Saag K, Bridges S, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:1-25.
  • Soliman MM, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2012;64:1108-15.
  • Strand V, et al. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Arth Res Ther. 2018; 20:129.
  • Strand V, et al. Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of life outcomes in patients with rheumatoid arthritis. RMD Open. 2018;4:e000602.
  • Smolen J, Breedveld F, Bermester G, et al.Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2015;75:3-15.
  • Schett G. Physiological effects of modulating the interleukin-6 axis. Rheumatology (Oxford). 2018 ; 57(suppl 2) : ii43-ii50
  • van Vollenhoven RF, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508-19.
  • Westhovens R, et al. Rheumatoid arthritis: Defining remission in patients with RA in clinical practice. Nature Reviews Rheumatology. 2012; 8: 445-447.


American College of Rheumatology:

EULAR – The European League Against Rheumatism:

Arthritis Foundation:

Rheumatology Research Foundation

World Health Organization

National Rheumatoid Arthritis Society


Toolkit Intro





Additional Reading